Wider-than-Expected Loss at Corcept - Analyst Blog
May 07 2013 - 7:40AM
Zacks
Corcept Therapeutics Inc. (CORT) posted a loss
per share of 11 cents in the first quarter of 2013, wider than the
Zacks Consensus Estimate of a loss of 10 cents. In the year-ago
quarter, Corcept reported a loss of 13 cents.
Corcept generated revenues of $1.7 million in the first quarter
of 2013, missing the Zacks Consensus Estimate of $3.0 million.
In Apr 2012, Corcept began offering its first product, Korlym
(mifepristone) 300 mg tablets after getting approval from the US
Food and Drug Administration (FDA) in Feb 2012.
Korlym, is approved in the US as a once-daily oral medication
for the treatment of hyperglycemia secondary to hypercortisolism in
adults suffering from endogenous Cushing’s syndrome, who have type
II diabetes or glucose intolerance.
We note that Corcept enjoys orphan drug designation for Korlym
from the FDA for the approved indication. This implies that the
drug enjoys marketing exclusivity for the indication in the US
until Feb 2019. Korlym was also approved by the European Commission
for the treatment of endogenous Cushing’s syndrome in Oct 2011.
Selling, general and administrative expenses were $8.4 million
in the first quarter of 2013, up 12.0% from the year-ago quarter.
The increase was mainly due to higher staffing, consultancy and
other professional services costs related to the commercialization
of Korlym.
Research and development expenses in the first quarter were $4.2
million, up from 20.2% from the year-ago quarter. The increase was
mainly due the expansion of the phase III trial mifepristone, the
active ingredient in Korlym, for the treatment of psychotic
depression along with the development of the company’s
next-generation selective GR-II antagonists.
We believe that the key objective for Corcept in 2013 will be
the successful commercialization of Korlym.
Corcept currently carries a Zacks Rank #3 (Hold). Pharma stocks,
which currently look attractive, include Santarus,
Inc. (SNTS), Onyx Pharmaceuticals, Inc.
(ONXX) and WuXi PharmaTech (Cayman) Inc. (WX). All
three carry a Zacks Rank #1 (Strong Buy).
CORCEPT THERAPT (CORT): Free Stock Analysis Report
ONYX PHARMA INC (ONXX): Free Stock Analysis Report
SANTARUS INC (SNTS): Free Stock Analysis Report
WUXI PHARMATECH (WX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Corcept Therapeutics (NASDAQ:CORT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Corcept Therapeutics (NASDAQ:CORT)
Historical Stock Chart
From Apr 2023 to Apr 2024